Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Short-term outcome following surgery for rare brain tumor entities in adults: a Swedish nation-wide registry-based study and comparison with SEER database

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. TERT promoter mutations in primary and secondary WHO grade III meningioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Expression of the stem cell marker CD133 in malignant meningioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Ki-67 Proliferation Index as a Marker of Time to Recurrence in Intracranial Meningioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jiri Bartek
  • Sanjay Dhawan
  • Erik Thurin
  • Ali Alattar
  • Sasha Gulati
  • Bertil Rydenhag
  • Roger Henriksson
  • Clark C Chen
  • Asgeir Store Jakola
Vis graf over relationer

OBJECTIVE: To investigate outcomes after surgery for rare brain tumors using the Swedish Brain Tumor Registry (SBTR).

METHODS: This is a nationwide study of patient in the SBTR, validated in the Surveillance, Epidemiology, and End Results (SEER) registries. We included all adults diagnosed 2009-2015 with a rare brain tumor entity (n = 216), defined as ependymoma (EP, n = 64), subependymoma (SUBEP, n = 21), ganglioglioma (GGL, n = 54), pilocytic astrocytoma (PA, n = 56) and primitive neuroectodermal tumor (PNET, n = 21). We analyzed symptomatology, tumor characteristics and outcomes.

RESULTS: Mean age was 38.3 ± 17.2 years in GGL, 36.2 ± 16.9 in PA, 37.0 ± 19.1 in PNET, 51.7 ± 16.3 in EP and 49.8 ± 14.3 in SUBEP. The most common symptom was focal deficit (39.6-71.4%), and this symptom was most common in GGL patients with 64.2% of GGL presenting with seizures. Most patients had no or little restriction in activity before surgery (Performance Status 0-1), although up to 15.0% of PNET patients had a performance status of 4. Gross total resection was achieved in most (> 50%) tumor categories. Incidence of new deficits was 11.1-34.4%. In terms of postoperative complications, 0-4.8% had a hematoma of any kind, 1.9-15.6% an infection, 0-7.8% a venous thromboembolism and 3.7-10.9% experienced a complication requiring reoperation. There were 3 deaths within 30-days of surgery, and a 1-year mortality of 0-14.3%.

CONCLUSION: We have provided benchmarks for the current symptomatology, tumor characteristics and outcomes after surgery for rare brain tumors as collected by the SBTR and validated our results in an independent registry. These results may aid in clinical decision making and advising patients.

OriginalsprogEngelsk
TidsskriftJournal of Neuro-Oncology
Vol/bind148
Udgave nummer2
Sider (fra-til)281-290
Antal sider10
ISSN0167-594X
DOI
StatusUdgivet - jun. 2020

ID: 61630169